ClinicalTrials.gg

Program

esreboxetine

Also written as “Esreboxetine”, “SS-RBX” and “AXS-14 (Esreboxetine)”.

Its studies are mostly in Fibromyalgia · Urinary Incontinence, Stress, led by 2 companies.

Furthest: phase 3, since Nov 20, 20088 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer60 open or runningphase 3since Nov 20, 2008Aug 26, 2005none ahead
Axsome Therapeutics22 open or runningphase 3since Feb 4, 2026Feb 4, 2026Mar 2028phase 3 · NCT07398417

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 26, 2005First studies: 2 phase 2 studies in Urinary Incontinence, StressNew to PfizerPfizer · NCT00138749, NCT00141128
  2. Sep 12, 2008Phase 2 study in FibromyalgiaPfizer · NCT00752505 · 89 enrolled · United States
  3. Nov 20, 2008Phase 3 study in FibromyalgiaPfizer · NCT00796601
  4. Dec 2, 20082 phase 1 studiesPfizer · NCT00800956, NCT00809289
  5. Feb 4, 2026Axsome Therapeutics's first study: phase 3 study in FibromyalgiaNew to Axsome TherapeuticsAxsome Therapeutics · NCT07398417 · 620 planned · United States
  6. Jun 4, 2026Phase 3 study in FibromyalgiaAxsome Therapeutics · NCT07637162 · 300 planned · United States

Ahead

  1. Mar 2028Primary completion: phase 3 study in FibromyalgiaAxsome Therapeutics · NCT07398417
  2. May 2028Primary completion: phase 3 study in FibromyalgiaAxsome Therapeutics · NCT07637162

TargetBeta

SLC6A2 →read by rule
“Norepinephrine transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC6A2

ProgramCompanyFurthest phaseStudies
lisdexamfetamineruleTakedaphase 447
BupropionruleGlaxoSmithKlinephase 429
dexmethylphenidaterulecingulate-therapeuticsphase 414
LevomilnacipranruleAbbViephase 413
AmphetamineruleTris Pharmaphase 48

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07637162Fibromyalgia · United States3By invitationAxsome TherapeuticsMay 2028300
NCT07398417Fibromyalgia · United States3RecruitingAxsome TherapeuticsMar 2028620
NCT00809289Fibromyalgia · Belgium1CompletedPfizerJul 200940
NCT00800956Healthy · United States1CompletedPfizerFeb 20094
NCT00796601Fibromyalgia3WithdrawnPfizerMay 1, 20100
NCT00752505Fibromyalgia · United States2CompletedPfizerJun 200989
NCT00141128Urinary Incontinence, Stress · Denmark2CompletedPfizer18
NCT00138749Urinary Incontinence, Stress · United States, Canada2CompletedPfizerAug 2006402

How it is read

Names in the registry

  • “Esreboxetine”, 3 entries
  • “SS-RBX”, 2 entries
  • “AXS-14 (Esreboxetine)”, 1 entry
  • “AXS-14 (esreboxetine)”, 1 entry
  • “esreboxetine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.